211 related articles for article (PubMed ID: 12538452)
21. Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer.
Schorge JO; Drake RD; Lee H; Skates SJ; Rajanbabu R; Miller DS; Kim JH; Cramer DW; Berkowitz RS; Mok SC
Clin Cancer Res; 2004 May; 10(10):3474-8. PubMed ID: 15161704
[TBL] [Abstract][Full Text] [Related]
22. Galectin-1: a link between tumor hypoxia and tumor immune privilege.
Le QT; Shi G; Cao H; Nelson DW; Wang Y; Chen EY; Zhao S; Kong C; Richardson D; O'Byrne KJ; Giaccia AJ; Koong AC
J Clin Oncol; 2005 Dec; 23(35):8932-41. PubMed ID: 16219933
[TBL] [Abstract][Full Text] [Related]
23. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling.
Wykoff CC; Pugh CW; Maxwell PH; Harris AL; Ratcliffe PJ
Oncogene; 2000 Dec; 19(54):6297-305. PubMed ID: 11175344
[TBL] [Abstract][Full Text] [Related]
24. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival.
Singhal H; Bautista DS; Tonkin KS; O'Malley FP; Tuck AB; Chambers AF; Harris JF
Clin Cancer Res; 1997 Apr; 3(4):605-11. PubMed ID: 9815727
[TBL] [Abstract][Full Text] [Related]
25. Stromal cell-derived factor-1alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor.
Zagzag D; Krishnamachary B; Yee H; Okuyama H; Chiriboga L; Ali MA; Melamed J; Semenza GL
Cancer Res; 2005 Jul; 65(14):6178-88. PubMed ID: 16024619
[TBL] [Abstract][Full Text] [Related]
26. Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia.
Gunningham SP; Currie MJ; Han C; Turner K; Scott PA; Robinson BA; Harris AL; Fox SB
Cancer Res; 2001 Apr; 61(7):3206-11. PubMed ID: 11306510
[TBL] [Abstract][Full Text] [Related]
27. Downregulation of Cap43 gene by von Hippel-Lindau tumor suppressor protein in human renal cancer cells.
Masuda K; Ono M; Okamoto M; Morikawa W; Otsubo M; Migita T; Tsuneyoshi M; Okuda H; Shuin T; Naito S; Kuwano M
Int J Cancer; 2003 Jul; 105(6):803-10. PubMed ID: 12767066
[TBL] [Abstract][Full Text] [Related]
28. Elevated plasma osteopontin levels in patients with hepatocellular carcinoma.
Kim J; Ki SS; Lee SD; Han CJ; Kim YC; Park SH; Cho SY; Hong YJ; Park HY; Lee M; Jung HH; Lee KH; Jeong SH
Am J Gastroenterol; 2006 Sep; 101(9):2051-9. PubMed ID: 16848813
[TBL] [Abstract][Full Text] [Related]
29. Endolymphatic sac tumors in patients with and without von Hippel-Lindau disease: the role of genetic mutation, von Hippel-Lindau protein, and hypoxia inducible factor-1alpha expression.
Jensen RL; Gillespie D; House P; Layfield L; Shelton C
J Neurosurg; 2004 Mar; 100(3):488-97. PubMed ID: 15035285
[TBL] [Abstract][Full Text] [Related]
30. Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma.
Hotte SJ; Winquist EW; Stitt L; Wilson SM; Chambers AF
Cancer; 2002 Aug; 95(3):506-12. PubMed ID: 12209742
[TBL] [Abstract][Full Text] [Related]
31. Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma.
Standal T; Hjorth-Hansen H; Rasmussen T; Dahl IM; Lenhoff S; Brenne AT; Seidel C; Baykov V; Waage A; Børset M; Sundan A; Hjertner O
Haematologica; 2004 Feb; 89(2):174-82. PubMed ID: 15003892
[TBL] [Abstract][Full Text] [Related]
32. Differential risk assessments from five hypoxia specific assays: The basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients.
Nordsmark M; Eriksen JG; Gebski V; Alsner J; Horsman MR; Overgaard J
Radiother Oncol; 2007 Jun; 83(3):389-97. PubMed ID: 17499868
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma.
Koopmann J; Fedarko NS; Jain A; Maitra A; Iacobuzio-Donahue C; Rahman A; Hruban RH; Yeo CJ; Goggins M
Cancer Epidemiol Biomarkers Prev; 2004 Mar; 13(3):487-91. PubMed ID: 15006928
[TBL] [Abstract][Full Text] [Related]
34. Strain and tumour specific variations in the effect of hypoxia on osteopontin levels in experimental models.
Lukacova S; Overgaard J; Alsner J; Horsman MR
Radiother Oncol; 2006 Aug; 80(2):165-71. PubMed ID: 16920210
[TBL] [Abstract][Full Text] [Related]
35. Osteopontin expression is an independent factor for poor survival in oral squamous cell carcinoma: a computer-assisted analysis on TMA sections.
Avirović M; Matušan-Ilijaš K; Damante G; Fabrro D; Cerović R; Juretić M; Grahovac B; Jonjić N; Lučin K
J Oral Pathol Med; 2013 Sep; 42(8):620-6. PubMed ID: 23438150
[TBL] [Abstract][Full Text] [Related]
36. [Correlation of osteopontin expression and laryngeal squamous cell carcinoma infiltration and metastasis].
Zhao Hongchun ; Wang Yanfei ; Zheng Tihua ; Che Juan ; Cao Ruijuan ; Wang Xia
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Sep; 29(17):1530-3. PubMed ID: 26647537
[TBL] [Abstract][Full Text] [Related]
37. Relationship between radiobiological hypoxia in a C3H mouse mammary carcinoma and osteopontin levels in mouse serum.
Lukacova S; Khalil AA; Overgaard J; Alsner J; Horsman MR
Int J Radiat Biol; 2005 Dec; 81(12):937-44. PubMed ID: 16524849
[TBL] [Abstract][Full Text] [Related]
38. Plasma osteopontin, hypoxia, and response to radiotherapy in nasopharyngeal cancer.
Hui EP; Sung FL; Yu BK; Wong CS; Ma BB; Lin X; Chan A; Wong WL; Chan AT
Clin Cancer Res; 2008 Nov; 14(21):7080-7. PubMed ID: 18981006
[TBL] [Abstract][Full Text] [Related]
39. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas.
Wiesener MS; Münchenhagen PM; Berger I; Morgan NV; Roigas J; Schwiertz A; Jürgensen JS; Gruber G; Maxwell PH; Löning SA; Frei U; Maher ER; Gröne HJ; Eckardt KU
Cancer Res; 2001 Jul; 61(13):5215-22. PubMed ID: 11431362
[TBL] [Abstract][Full Text] [Related]
40. Expression of haptoglobin predicts recurrence in head and neck squamous cell carcinoma.
Lee CC; Ho HC; Lee MS; Hung SK; Yu CC; Su YC
Clin Chim Acta; 2010 Aug; 411(15-16):1116-21. PubMed ID: 20417195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]